News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
615,626 Results
Type
Article (47385)
Company Profile (244)
Press Release (567997)
Section
Business (177017)
Career Advice (2574)
Deals (32592)
Drug Delivery (117)
Drug Development (78865)
Employer Resources (161)
FDA (16233)
Job Trends (13611)
News (313428)
Policy (32443)
Tag
Academia (2408)
Alliances (44660)
Alzheimer's disease (1332)
Approvals (16157)
Artificial intelligence (151)
Bankruptcy (318)
Best Places to Work (10149)
Biotechnology (130)
Breast cancer (186)
Cancer (1371)
Cardiovascular disease (113)
Career advice (2143)
Cell therapy (295)
Clinical research (63113)
Collaboration (463)
Compensation (264)
COVID-19 (2624)
C-suite (108)
Data (1341)
Diabetes (178)
Diagnostics (5479)
Drug pricing (106)
Earnings (68817)
Employer resources (146)
Events (92948)
Executive appointments (378)
FDA (16909)
Funding (382)
Gene therapy (209)
GLP-1 (693)
Government (3965)
Healthcare (15926)
Infectious disease (2720)
Inflammatory bowel disease (115)
Interviews (471)
IPO (15203)
Job creations (3858)
Job search strategy (1803)
Layoffs (468)
Legal (7829)
Lung cancer (207)
Lymphoma (102)
Manufacturing (221)
Medical device (11448)
Medtech (11452)
Mergers & acquisitions (17552)
Metabolic disorders (515)
Neuroscience (1676)
NextGen Class of 2024 (5516)
Non-profit (3424)
Northern California (1625)
Obesity (300)
Opinion (234)
Patents (121)
People (51682)
Phase I (19414)
Phase II (27418)
Phase III (21385)
Pipeline (523)
Postmarket research (2607)
Preclinical (7905)
Radiopharmaceuticals (233)
Rare diseases (272)
Real estate (5390)
Regulatory (22171)
Research institute (2223)
Resumes & cover letters (426)
Southern California (1375)
Startups (3324)
United States (14269)
Vaccines (643)
Weight loss (238)
Date
Last 7 days (593)
Last 30 days (2232)
Last 365 days (33836)
2024 (33690)
2023 (37956)
2022 (48577)
2021 (52358)
2020 (49731)
2019 (40561)
2018 (30960)
2017 (31274)
2016 (30064)
2015 (33729)
2014 (27400)
2013 (23041)
2012 (24703)
2011 (25297)
2010 (23250)
Location
Africa (781)
Arizona (157)
Asia (38410)
Australia (6185)
California (3596)
Canada (1280)
China (280)
Colorado (167)
Connecticut (188)
Europe (86633)
Florida (512)
Georgia (118)
Illinois (345)
Indiana (194)
Maryland (612)
Massachusetts (2868)
Michigan (140)
Minnesota (256)
New Jersey (1061)
New York (1002)
North Carolina (738)
Northern California (1625)
Ohio (123)
Pennsylvania (850)
South America (1158)
Southern California (1375)
Texas (512)
Washington State (380)
615,626 Results for "galderma pharma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
December 13, 2024
·
14 min read
Press Releases
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
November 28, 2024
·
10 min read
Press Releases
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
December 16, 2024
·
14 min read
Press Releases
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
October 21, 2024
·
9 min read
FDA
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
September 9, 2024
·
4 min read
Immunology and inflammation
Galderma’s IL-31 Injection Wins FDA Approval for Skin Disorder Prurigo Nodularis
The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.
August 13, 2024
·
2 min read
·
Tristan Manalac
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Deals
Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters
Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.
December 13, 2024
·
1 min read
·
Annalee Armstrong
Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
Galderma announced that the U.S. Food and Drug Administration has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.
February 14, 2024
·
11 min read
CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
Galderma announced that the U.S. Food and Drug Administration has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.
February 14, 2024
·
12 min read
1 of 61,563
Next
